企業プロフィール
Arbutus 株価・ニュース・カタリスト
- ティッカー:
- ABUS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Canada
株価パフォーマンス
4.71 USD (+0.86%)
終値
最終更新: 2026年8月17日
842M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ABUS closed up 0.86% at $4.71. No new same-company headline was identified in the current news window.
企業概要
Hepatitis B Therapeutics
Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference.
Imdusiran
Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen. Clinical studies have evaluated it alone and with immune-modulating agents to seek durable off-treatment control.
Phase 2b Strategy
Arbutus has aligned with the FDA on the design and safety parameters of a proposed Phase 2b study of imdusiran. The company is incorporating that feedback into the final clinical protocol.
LNP Intellectual Property
Arbutus retains economic interests in lipid nanoparticle intellectual property through Genevant and related licensing, settlement, and patent-enforcement activities. These rights are separate from its internal hepatitis B development program.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。